The Department of Health published a further Health Services Circular (HSC 1998/147). This document considered specific arrangements for health authorities to submit claims for additional funding to provide recombinant Factor 8. Read more about The Department of Health published a further Health Services Circular (HSC 1998/147). This document considered specific arrangements for health authorities to submit claims for additional funding to provide recombinant Factor 8.
A Health Services Circular (HSC 1998/999) was published. This promulgated the announcement that central funding would be provided to health authorities in order to provide recombinant Factor 8 to new patients as well as patients under the age of 16. Read more about A Health Services Circular (HSC 1998/999) was published. This promulgated the announcement that central funding would be provided to health authorities in order to provide recombinant Factor 8 to new patients as well as patients under the age of 16.
One man wrote to Tony Blair expressing his concern that his son's haemophilia treatment might revert to human-derived plasma after he reached the age threshold, as well as expressing further concerns about the affordability of recombinant Factor 8. Read more about One man wrote to Tony Blair expressing his concern that his son's haemophilia treatment might revert to human-derived plasma after he reached the age threshold, as well as expressing further concerns about the affordability of recombinant Factor 8.
Carol Grayson wrote to Frank Dobson to enquire about plans to roll out recombinant to all patients, but was told in reply that "there are no plans to arrange this centrally" and that "the Department of Health does not accept that the clinical case has been made for the general use of the recombinant product". Read more about Carol Grayson wrote to Frank Dobson to enquire about plans to roll out recombinant to all patients, but was told in reply that "there are no plans to arrange this centrally" and that "the Department of Health does not accept that the clinical case has been made for the general use of the recombinant product".
Dr Graham Winyard and Dr Metters sent a memo to Baroness Jay regarding New Variant CJD and Blood. Read more about Dr Graham Winyard and Dr Metters sent a memo to Baroness Jay regarding New Variant CJD and Blood.
An Information Pack produced by the South Wales Haemophilia Group referred to their success in campaigning for Recombinant treatment for all haemophiliacs in Wales. Read more about An Information Pack produced by the South Wales Haemophilia Group referred to their success in campaigning for Recombinant treatment for all haemophiliacs in Wales.
Beverley Tumelty set out the role her late brother, Gareth Lewis, played in campaigning for recombinant treatment for haemophiliacs in Wales. He was Chairman of the South Wales Haemophilia Group during this period. Read more about Beverley Tumelty set out the role her late brother, Gareth Lewis, played in campaigning for recombinant treatment for haemophiliacs in Wales. He was Chairman of the South Wales Haemophilia Group during this period.
Concerns were raised at a meeting between the Haemophilia Society and Department of Health that access to recombinant Factor 8 was not equal. Read more about Concerns were raised at a meeting between the Haemophilia Society and Department of Health that access to recombinant Factor 8 was not equal.
Dr Ludlum raised concerns about the inequality of haemophilia care across the UK, in particular that of the very uneven availability of recombinant factor VIII. Read more about Dr Ludlum raised concerns about the inequality of haemophilia care across the UK, in particular that of the very uneven availability of recombinant factor VIII.
Jan Wallace described her involvement in Haemophilia Wales' campaign in 1997 which aimed to "ensure all haemophiliacs in Wales received the safest treatment known as Recombinant". Read more about Jan Wallace described her involvement in Haemophilia Wales' campaign in 1997 which aimed to "ensure all haemophiliacs in Wales received the safest treatment known as Recombinant".